Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
Tumiati M, Hietanen S, Hynninen J, Pietilä E, Färkkilä A, Kaipio K, Roering P, Huhtinen K, Alkodsi A, Li Y, Lehtonen R, Erkan EP, Tuominen MM, Lehti K, Hautaniemi SK, Vähärautio A, Grénman S, Carpén O, Kauppi L. Tumiati M, et al. Among authors: farkkila a. Clin Cancer Res. 2018 Sep 15;24(18):4482-4493. doi: 10.1158/1078-0432.CCR-17-3770. Epub 2018 Jun 1. Clin Cancer Res. 2018. PMID: 29858219
Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Müllerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors.
Haltia UM, Hallamaa M, Tapper J, Hynninen J, Alfthan H, Kalra B, Ritvos O, Heikinheimo M, Unkila-Kallio L, Perheentupa A, Färkkilä A. Haltia UM, et al. Among authors: farkkila a. Gynecol Oncol. 2017 Jan;144(1):83-89. doi: 10.1016/j.ygyno.2016.11.018. Epub 2016 Nov 18. Gynecol Oncol. 2017. PMID: 27871721
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
Parmar K, Kochupurakkal BS, Lazaro JB, Wang ZC, Palakurthi S, Kirschmeier PT, Yang C, Sambel LA, Färkkilä A, Reznichenko E, Reavis HD, Dunn CE, Zou L, Do KT, Konstantinopoulos PA, Matulonis UA, Liu JF, D'Andrea AD, Shapiro GI. Parmar K, et al. Among authors: farkkila a. Clin Cancer Res. 2019 Oct 15;25(20):6127-6140. doi: 10.1158/1078-0432.CCR-19-0448. Epub 2019 Aug 13. Clin Cancer Res. 2019. PMID: 31409614 Free PMC article.
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Färkkilä A, Gulhan DC, Casado J, Jacobson CA, Nguyen H, Kochupurakkal B, Maliga Z, Yapp C, Chen YA, Schapiro D, Zhou Y, Graham JR, Dezube BJ, Munster P, Santagata S, Garcia E, Rodig S, Lako A, Chowdhury D, Shapiro GI, Matulonis UA, Park PJ, Hautaniemi S, Sorger PK, Swisher EM, D'Andrea AD, Konstantinopoulos PA. Färkkilä A, et al. Nat Commun. 2020 Mar 19;11(1):1459. doi: 10.1038/s41467-020-15315-8. Nat Commun. 2020. PMID: 32193378 Free PMC article. Clinical Trial.
Functional Profiling of FSH and Estradiol in Ovarian Granulosa Cell Tumors.
Haltia UM, Pihlajoki M, Andersson N, Mäkinen L, Tapper J, Cervera A, Horlings HM, Turpeinen U, Anttonen M, Bützow R, Unkila-Kallio L, Carpén O, Wilson DB, Heikinheimo M, Färkkilä A. Haltia UM, et al. Among authors: farkkila a. J Endocr Soc. 2020 Mar 16;4(4):bvaa034. doi: 10.1210/jendso/bvaa034. eCollection 2020 Apr 1. J Endocr Soc. 2020. PMID: 32309755 Free PMC article.
60 results